Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 51 Prostatic Neoplasms 23 Lung Neoplasms 17 Breast Neoplasms 15 Squamous Cell Carcinoma of Head and Neck 13 Stomach Neoplasms 10 Parkinson Disease 4, Autosomal Dominant Lewy Body 8 Neoplasms 8 Urinary Bladder Neoplasms 6 Carcinoma, Transitional Cell 6 Triple Negative Breast Neoplasms 5 Non-Muscle Invasive Bladder Neoplasms 5 Neoplasm Metastasis 5 Head and Neck Neoplasms 5 Carcinoma, Squamous Cell 5 Prostatic Neoplasms, Castration-Resistant 4 Ovarian Neoplasms 4 Oropharyngeal Neoplasms 4 Endometrial Neoplasms 4 Small Cell Lung Carcinoma 3 Salivary Gland Neoplasms 3 Nasopharyngeal Carcinoma 3 Laryngeal Neoplasms 3 HER2-positive Breast Cancer 3 Fallopian Tube Neoplasms 3 Anatomic Stage I Breast Cancer AJCC v8 3 Adenocarcinoma 3 Solid Tumors 2 Sarcoma 2 Osteosarcoma 2

Interventions

Cyclophosphamide 25 fludarabine 19 Dexamethasone 17 pembrolizumab 13 Rituximab 12 venetoclax 9 Lenalidomide 9 Gemcitabine 9 Etoposide 9 pomalidomide 8 Vincristine 7 glofitamab 6 fludarabine phosphate 6 carfilzomib 6 Temozolomide 6 obinutuzumab 5 daratumumab 5 Prednisone 5 Nivolumab 5 Doxorubicin 5 Cisplatin 5 Calcium Dobesilate 5 Bortezomib 5 zanubrutinib 4 selinexor 4 Immunotherapy, Adoptive 4 Cytarabine 4 Carboplatin 4 Azacitidine 4 ruxolitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Docetaxel × 90 days × Clear all

NCT06551324 2026-05-05

MEVPRO-1

Pfizer

Phase 3 Active not recruiting

Prostatic Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡